TL;DR
HLA-A24&-E dual integrated HPV-rejTs are developed that effectively suppress recipient immune rejection while maintaining more robust cytotoxicity than original cytotoxic T lymphocytes, contributing to feasible “off-the-shelf” T cell therapy with robust anti-cervical cancer effects.
AI-generated by Semantic Scholar
Authors
Yoshiki Furukawa, Midori Ishii, Jun Ando, Kazuya Ikeda, Kyomi J. Igarashi, Shintaro Kinoshita, Yoko Azusawa, Tokuko Toyota, Tadahiro Honda, Mahito Nakanishi, Koichi Ohshima, Ayako Masuda, Emiko Yoshida, Mari Kitade, Matthew Porteus, Yasuhisa Terao, Hiromitsu Nakauchi, Miki Ando